Resonance Specialties Limited reported a sharp 252% year-on-year surge in net profit to ₹574.42 lakhs for the quarter ended June 30, 2026, driven primarily by a doubling of international revenues. The Board of Directors, meeting on August 4, 2026, approved the unaudited financial results and simultaneously greenlit the acquisition of a strategic manufacturing facility in Madhya Pradesh for ₹29.98 crores. This dual announcement signals both strong operational performance and aggressive capacity expansion through vertical integration.

Financial Performance Highlights

Revenue from operations rose to ₹3,258.41 lakhs in Q1FY27, up from ₹2,127.42 lakhs in the corresponding period of FY26. Total income stood at ₹3,312.19 lakhs, including other income of ₹53.78 lakhs. Profit before tax jumped to ₹764.93 lakhs from ₹237.24 lakhs year-ago. The company’s basic and diluted earnings per share (EPS) were ₹4.98 each, compared to ₹1.41 in Q1FY26.

Expense Management and Margins

Total expenses increased to ₹2,547.26 lakhs from ₹1,912.89 lakhs, reflecting higher input costs associated with increased production volumes. Key expense components included cost of materials consumed at ₹1,360.36 lakhs and conversion charges at ₹332.13 lakhs. Employee benefits expense rose to ₹161.93 lakhs from ₹141.96 lakhs. Finance costs remained negligible at ₹1.27 lakhs. The expansion in revenue outpaced the rise in expenses, leading to improved operating leverage.

Export-Led Growth

The primary driver of the financial performance was robust international demand. Revenue from outside India more than doubled to ₹2,326.08 lakhs from ₹1,065.49 lakhs in Q1FY26, accounting for approximately 71% of total revenue. Domestic revenue from India declined slightly to ₹932.33 lakhs from ₹1,061.93 lakhs. This shift underscores the company’s growing reliance on global markets for specialty chemicals and APIs.

Acquisition of Mandideep Facility

In a significant strategic move, Resonance Specialties approved the purchase of a manufacturing facility at Plot No. 6, New Industrial Area-II, Mandideep, Madhya Pradesh, from Kaygee Laboratories Private Limited (KLPL), a promoter group entity. The transaction, valued at ₹29.98 crores on a slump sale basis, includes leasehold land of 22,304 sq. mtrs., industrial buildings of 5,227 sq. mtrs., plant machinery, licenses, and employees.

The facility, originally set up in 1990, has been supplying chemical intermediates and APIs to Resonance Specialties on a job work basis. It was recently inspected and approved by WHO, Geneva. The acquisition aims to secure uninterrupted production, enhance operational control, and eliminate outsourcing costs. Shareholder approval is required for the transaction, which is expected to be completed by November 30, 2026. The deal is structured as an arm’s length related party transaction based on an independent valuer’s certificate.

Auditor’s Review and Compliance

The unaudited financial results were reviewed by Kailash Chand Jain & Co., Chartered Accountants, who issued a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors noted no material misstatements. The results were prepared in accordance with Ind AS-34 and reviewed by the audit committee before Board approval. As of June 30, 2026, the company has no subsidiaries, associates, or joint ventures.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE486D01017/1e4cca1b-2470-47b7-87cc-73573d40d388.pdf

Resonance Specialties shareholders approved a final dividend of ₹1 per share and authorized related party transactions worth up to ₹40 crore during its 37th Annual General Meeting held on August 4, 2026. The virtual meeting, presided over by Chairman Raj Kamal Prasad Verma, also saw the re-appointment of Director Charchit Jain and Statutory Auditors Kailash Chand Jain & Co., signaling continuity in governance for the pharma ingredients manufacturer.

The Board of Directors proposed the dividend at 10% on the face value of ₹10 per equity share. This payout reflects the company’s commitment to returning capital to shareholders while maintaining operational stability. The approval process followed electronic voting conducted between July 31, 2026, and August 3, 2026, with July 28, 2026, as the cut-off date for determining voting entitlements. M/s Alok Khairwar & Associates served as the scrutinizer for the remote e-voting process under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Resolutions Passed

Shareholders voted on several ordinary and special business items during the AGM. The key outcomes include:

The most significant special resolution concerned the approval for entering into related party transactions during any financial year not exceeding an aggregate amount of ₹40 crore with Kaygee Laboratories Private Limited. This cap provides the management with flexibility to execute necessary commercial agreements without seeking fresh shareholder approval for each transaction, provided the total does not breach the limit.

Governance and Compliance

The meeting adhered to strict regulatory compliance standards. Representatives from the Statutory Auditors, Secretarial Auditors, and the Scrutinizer were present via video conference. Chairman Raj Kamal Prasad Verma confirmed that the quorum was present throughout the session. He noted that there were no qualifications, adverse remarks, or observations in the Independent Auditors Report or the Secretarial Audit Report, indicating clean compliance for the period ended March 31, 2026.

The Whole-time Director addressed queries from members during the Q&A session before the e-voting module remained open for an additional 15 minutes for attendees who had not voted remotely. The meeting concluded at 1:20 p.m. Following the receipt of the scrutinizer’s report, the results were declared and posted on the company’s website and displayed at its registered office in Mumbai.

What the Numbers Show

The decision to declare a ₹1 per share dividend represents a modest return to equity holders, consistent with the company’s conservative capital allocation strategy. By capping related party transactions at ₹40 crore, the board has established a clear transparency boundary for dealings with Kaygee Laboratories Private Limited, ensuring that significant commercial ties remain subject to annual shareholder oversight rather than indefinite open-ended approvals.